CO2018000349A2 - Interleukin receptor peptide inhibitors 23 - Google Patents
Interleukin receptor peptide inhibitors 23Info
- Publication number
- CO2018000349A2 CO2018000349A2 CONC2018/0000349A CO2018000349A CO2018000349A2 CO 2018000349 A2 CO2018000349 A2 CO 2018000349A2 CO 2018000349 A CO2018000349 A CO 2018000349A CO 2018000349 A2 CO2018000349 A2 CO 2018000349A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino acid
- peptide inhibitors
- receptor peptide
- interleukin receptor
- absent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente invención proporciona inhibidores peptídicos del receptor de interleucina 23, los cuales comprenden una secuencia de aminoácidos de fórmula (Xa): X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20 (Xa), en la que: X1, X2 y X3 son cualquier aminoácido o se encuentran ausentes; X4 es cualquier aminoácido o resto químico que pueda formar un enlace con X9; X5, X6, X7 y X8 son cualquier aminoácido;X9 es cualquier aminoácido o resto químico que pueda formar un enlace con X4; X10, X11, X12, X13, X14 y X15 son cualquier aminoácido; y X16, X17, X18, X19 y X20 son cualquier aminoácido o se encuentran ausentes; en donde los inhibidores peptídicos se ciclan mediante un enlace entre X4 y X9. Asimismo, se proporcionan polinucleótidos que codifican dichos inhibidores peptídicos, vectores que comprenden dichos polinucleótidos, y composiciones farmacéuticas que comprenden dichos inhibidores peptídicos.The present invention provides peptide inhibitors of the interleukin 23 receptor, which comprise an amino acid sequence of formula (Xa): X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 -X14-X15-X16-X17-X18-X19-X20 (Xa), in which: X1, X2 and X3 are any amino acid or are absent; X4 is any amino acid or chemical moiety that can form a bond with X9; X5, X6, X7 and X8 are any amino acid; X9 is any amino acid or chemical moiety that can form a bond with X4; X10, X11, X12, X13, X14 and X15 are any amino acid; and X16, X17, X18, X19 and X20 are any amino acid or are absent; wherein the peptide inhibitors are cycled through a link between X4 and X9. Likewise, polynucleotides encoding said peptide inhibitors, vectors comprising said polynucleotides, and pharmaceutical compositions comprising said peptide inhibitors are provided.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US201562264820P | 2015-12-08 | 2015-12-08 | |
US201662281123P | 2016-01-20 | 2016-01-20 | |
PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018000349A2 true CO2018000349A2 (en) | 2018-07-10 |
Family
ID=57757647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0000349A CO2018000349A2 (en) | 2015-07-15 | 2018-01-15 | Interleukin receptor peptide inhibitors 23 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP3341011A4 (en) |
JP (1) | JP6858174B2 (en) |
KR (1) | KR102513978B1 (en) |
CN (1) | CN108348580B (en) |
AU (1) | AU2016293619B2 (en) |
BR (1) | BR112018000691A2 (en) |
CA (1) | CA2991984A1 (en) |
CL (3) | CL2018000128A1 (en) |
CO (1) | CO2018000349A2 (en) |
CR (1) | CR20180029A (en) |
DO (1) | DOP2018000010A (en) |
EA (1) | EA035733B9 (en) |
EC (1) | ECSP18002929A (en) |
HK (2) | HK1257747A1 (en) |
IL (1) | IL256827A (en) |
MX (1) | MX2018000542A (en) |
NI (1) | NI201800008A (en) |
PE (1) | PE20180571A1 (en) |
PH (1) | PH12018500086A1 (en) |
SG (1) | SG10201912066SA (en) |
SV (1) | SV2018005614A (en) |
UA (1) | UA123772C2 (en) |
WO (1) | WO2017011820A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3176170T (en) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
PE20152033A1 (en) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | BICYCLE HETEROCYCLES AS FGFR INHIBITORS |
CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
KR102482790B1 (en) | 2014-07-17 | 2022-12-29 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
MX2017004300A (en) | 2014-10-01 | 2017-12-18 | Protagonist Therapeutics Inc | NOVEL A4ß7 PEPTIDE MONOMER AND DIMER ANTAGONISTS. |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
EP3570864A4 (en) * | 2017-01-18 | 2020-12-30 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
CN112867716A (en) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Solid forms of FGFR inhibitors and methods for their preparation |
TW202019948A (en) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化(上海)新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN114341161A (en) * | 2019-07-10 | 2022-04-12 | 领导医疗有限公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
JOP20220083A1 (en) | 2019-10-14 | 2023-01-30 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
EP4090670A1 (en) | 2020-01-15 | 2022-11-23 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
JP7397239B2 (en) * | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ.ベー. | Compositions of peptide inhibitors of interleukin-23 receptors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
AU2022310347A1 (en) * | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Bicyclic peptide inhibitors of interleukin-23 receptor |
TW202332682A (en) | 2021-12-01 | 2023-08-16 | 丹麥商西蘭製藥公司 | Peptide inhibitors of interleukin-23 receptor |
WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
KR20090119876A (en) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon/glp-1 receptor co-agonists |
EP2288621A4 (en) * | 2007-07-06 | 2012-01-04 | Valorisation Hsj Soc En Commandite | Il-23 receptor antagonists and uses thereof |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
CA2926685A1 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
KR102482790B1 (en) | 2014-07-17 | 2022-12-29 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active IP Right Grant
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/en unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en active Search and Examination
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018000349A2 (en) | Interleukin receptor peptide inhibitors 23 | |
EA201792500A1 (en) | AAV-MEDIATED EXPRESSION OF ANTIBODIES AGAINST FLU AND METHODS OF THEIR USE | |
CU20180062A7 (en) | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | |
MX2018015699A (en) | Cannabinoid formulations. | |
CY1121891T1 (en) | GENETICALLY MODIFIED PHENYLALANINE-AMMONIA LYASE POLYPEPTIDES | |
CO2018005525A2 (en) | Aqueous pharmaceutical formulation of the anti-pd-l1 avelumab antibody | |
CL2018001478A1 (en) | Apeline receptor agonists and methods of use | |
DOP2016000042A (en) | ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME | |
EA201490039A1 (en) | CHEMERIC AND HYBRID POLYPEPTIDES OF FACTOR VIII AND METHODS OF THEIR APPLICATION | |
CL2011003147A1 (en) | Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer. | |
MX2019013123A (en) | Oral dosing of glp-1 compounds. | |
AR106144A1 (en) | A PROTEIN CONJUGATE THAT INCLUDES PHYSIOLOGICAL POLIPEPTIDES AND AN IMMUNOGLOBULIN FC REGION | |
MX2019000140A (en) | Xylanase variants and polynucleotides encoding same. | |
CO2018012258A2 (en) | Mic-1 compounds and uses of these | |
MX2019013289A (en) | Engineered ligase variants. | |
UA116431C2 (en) | COMPOSITION FOR PREVENTION OF INFECTION MYCOPLASMA SPP. | |
PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
CL2017001120S1 (en) | Dental positioner (divisional application 18-2016) | |
CY1123738T1 (en) | ADDITIVES THAT ENHANCE THE BIOACTIVITY OF GONADOTROPINS | |
EA201791174A1 (en) | ANTIMICOTIC CONNECTION | |
MA41453A (en) | ENCAPSULATION OF VERY POWERFUL ACTIVE AGENTS | |
CL2018000290A1 (en) | Cgrp receptor antagonists | |
EA201791024A1 (en) | CONJUGATES OF BIOMOLECULES | |
DK3322430T3 (en) | ANTI-INFLAMMATORY PEPTIDES, AND APPLICATIONS THEREOF | |
BR112015020079A8 (en) | COMPOSITIONS FOR ORAL CARE |